InnoCare Pharma (688428.SH) plans to collaborate with Eli Lilly to develop innovative drugs, with potential R&D and commercialization milestone payments of approximately US$3.25 billion.

Zhitong Finance APP News, InnoCare Pharma (688428.SH) announced that its wholly-owned subsidiary, Beijing InnoCare Pharma Tech Co., Ltd., has signed a research collaboration and license agreement with Eli Lilly and Company (hereinafter referred to as "Lilly"). The two parties will carry out strategic cooperation in the field of innovative drug research and development. The company will rely on its proprietary drug discovery platform and deep research experience to discover and develop up to 5 innovative target projects to address major unmet clinical needs.